Global Inhalation Sedatives Market

The respiratory devices and equipment (therapeutic) market consists of sales of respiratory devices and equipment used to treat patients with acute or chronic respiratory disorders such as chronic obstructive pulmonary disease (COPD), chronic bronchitis, asthma, sleep disorders, etc. The market includes the sales of respiratory monitoring devices establishments primarily engaged in the manufacturing of nebulizers, humidifiers, oxygen concentrators, positive airway pressure devices, ventilators, capnographs, and gas analyzers. The therapeutic respiratory devices and equipment market covered in this report is segmented by product into nebulizers, humidifiers, oxygen concentrators, positive airway pressure devices, ventilators, capnographs, gas analyzers; by end-user into homecare settings, hospitals; by technology into HEPA filter, electrostatic filtration, microsphere separation, hollow fiber filtration, others. The global respiratory devices and equipment (therapeutic) market is expected to decline from $33.97 billion in 2020 to $24.71 billion in 2021 at a compound annual growth rate (CAGR) of -27.3%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The respiratory devices and equipment market is expected to reach $45.81 billion in 2025 at a CAGR of 16.7%. The market for respiratory devices and equipment is expected to expand rapidly. The fact that COVID-19 is essentially a respiratory ailment has boosted the use of respiratory monitoring devices, in turn contributing to the growth of this market. Currently, there is a huge demand for respiratory devices including ventilators, especially in developing countries. Companies across the globe are focusing on increasing the availability of ventilators, nebulizers and other respiratory support devices for the patients. Rising prevalence of respiratory diseases such as Chronic Obstructive Pulmonary Disorder (COPD) and sleep apnea contributed to the growth of the therapeutic respiratory devices and equipment market. According to World Health Organization, one million people die due to chronic obstructive pulmonary diseases caused by smoking among the 4.9 million people who die due to tobacco consumption and 65 million people suffer with moderate to severe COPD. As per its estimates, COPD is predicted to be the third leading cause of death worldwide and potentially fatal respiratory diseases. Tuberculosis, COPD, and lung cancer will account for about one in five deaths worldwide by 2030. According to National Health Interview Survey, 2018 by Centers for Disease Control and Prevention (CDC), number of adults with diagnosed chronic bronchitis in the USA was 9.0 million. In the USA, it is estimated that 22 million Americans suffer from sleep apnea, with 80% of the cases of moderate and severe obstructive sleep apnea undiagnosed. According to epidemiological studies presented at the Associated Professional Sleep Societies in 2019, 37% of adults in the North, Central and South America suffer from Obstructive sleep apnea (OSA). The increased prevalence of COPD and sleep apnea in geriatric population is driving the market for therapeutic respiratory devices. Lack of awareness regarding the usage of respiratory devices have always been a major challenge in the therapeutic respiratory device market. Outcomes for patients with chronic respiratory diseases remain poor despite the development of novel therapies. An International Survey conducted on Noninvasive Ventilation Use for Acute Respiratory Failure in General Non-Monitored Wards in 51 countries from 5 continents revealed that 44% of the GPs and physicians reported that they had never performed spirometry to make a diagnosis of COPD and the NIV application in general wards was reported by only 66% of respondents. Limited training and human resources were the most common reasons for not using NIV in general wards. The lack of awareness on the use of the respirating devices is negatively affecting the respiratory devices and therapeutic market. The companies in the respiratory devices and equipment therapeutic market are increasingly using AI to develop respiratory devices to treat Asthma and COPD. Artificial intelligence supports the development of innovative sensors-equipped inhalers which helps patients to track their dosage intake. These sensors are durable and consume less power and help caution the patients by noting the differences or fluctuations in the respiration. These are used for both add-on and embedded inhalers. These inhalers with sensors can track data automatically and can alert both the doctors and patients about the health condition of the patients. Also, the companies in developing devices such as AI aided imaging systems and AI aided platforms that will act as voice biomarkers. For instance, Verbal and Healthymize, two early-stage Israeli AI healthtech companies, announced a merger in 2019 to create a joint company (Vocalis Health) that will be a global leader in vocal biomarkers which develops an artificial intelligence-based platform that uses voice interaction through a call center or smart device to passively screen and monitor millions of patients that live with a range of voice-affecting diseases, like chronic respiratory or cardiac conditions or depression. In March 2020, Masimo, a global leader in noninvasive monitoring technologies acquired NantHealth, Inc's connected care business for an undisclosed amount. NantHealth is a provider a tablet-optimized application that sits on top of our DCX platform to provide clinicians more convenient and ubiquitous access to capture a wide array of patient vitals such as respiratory rate, blood pressure and heart rate in addition to performing patient assessments. This move of Masimo will leverage its capabilities with NantHealth’s solutions that can enable a more efficient patient rounding and assessment workflow by providing a near real-time stream of data from the patient's bedside unlike periodic sampling typically entered into an EHR hours later. Major players in the respiratory devices and equipment market are Hamilton Medical Ag, Koninklijke Philips N.V, Smiths Medica, Ge Healthcare, Philips Health Care, Chart Industries, Invacare Corporation, Fisher & Paykel Healthcare Limited, ResMed, and Dragerwerk Ag. The regions covered in the respiratory devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the respiratory devices and equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global respiratory devices and equipment (therapeutic) market is segmented - 1) By Product: Nebulizers, Humidifiers, Oxygen Concentrators, Positive Airway Pressure Devices, Ventilators, Capnographs, Gas Analyzers 2) By End-User: Homecare Settings, Hospitals 3) By Technology: HEPA Filter, Electrostatic Filtration, Microsphere Separation, Hollow Fiber Filtration, Others

The respiratory monitoring devices market consists of sales of respiratory monitoring devices used to monitor respiration related parameters that aid the detection of acute or chronic respiratory disorders. The respiratory monitoring devices establishments are primarily engaged in the manufacturing of capnographs, gas analyzers, pulse oximeters, peak flow meters, spirometers, and polysomnography. The market covered in the respiratory monitoring devices market report is segmented by type into capnographs, gas analyzers, pulse oximeters, peak flow meters, spirometers, polysomnographs, others; by end-user into laboratories, hospitals, home use; by application into chronic obstructive pulmonary disease (COPD), infectious diseases, asthma, others. The global respiratory monitoring devices market is expected to decline from $1.86 billion in 2020 to $1.72 billion in 2021 at a compound annual growth rate (CAGR) of -7.5%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The respiratory monitoring devices market is expected to reach $2.32 billion in 2025 at a CAGR of 7.8%. The market for respiratory monitoring devices is experiencing an exponential growth due to the COVID-19 pandemic. The fact that COVID-19 is essentially a respiratory ailment has boosted the use of respiratory monitoring devices, to monitor the physiological functions of lungs during COVID-19 treatment. Rising rate of chronic respiratory diseases is expected to drive the respiratory monitoring devices market in near future. The chronic respiratory diseases such as asthma, bronchitis, pneumonia and others resulting from different bacterial and viral infections will boost the demand of respiratory monitoring devices. For example, in 2019, 334 million people worldwide suffered with asthma and 65 million suffered with chronic obstructive pulmonary disease (COPD). The respiratory monitoring devices such as spirometers and pulse oximeters act as essential devices to monitor vital respiratory parameters. Longer duration of time taken in the approval process of respiratory devices is restricting the growth of respiratory monitoring devices market. Before a new respiratory device is introduced to the market, it takes 7.2 months for the FDA approval process, which adds to the development costs to be borne by device manufacturers, thus acting as a restraint to the market growth. To reduce incidences associated with the respiratory devices and ensure that the devices are safe and have least adverse reactions, regulatory authorities such as Medicines and Healthcare products Regulatory Agency (MRHA) in the UK regulates and monitors the devices by restricting devices for use and sending field safety notices to correct the devices. These stringent approval processes and regulatory policies may impact the respiratory monitoring devices market. The companies in the market are increasingly launching smart respiratory monitoring devices to diagnose and monitor number of respiratory diseases. These smart respiratory monitoring devices are Bluetooth-enabled which can be connected to smartphones to continuously monitor the vital respiratory parameters. For instance, in November 2019, Lupin Limited, India-based pharmaceutical company, introduced Adhero, a new connected smart device for metered-dose medications. This first-of-its-kind technology is intended to help people with chronic respiratory illnesses monitor their use of MDI and to promote enhanced therapy adherence. In May 2019, Apple, a USA based technology company acquired Tueo Health for an undisclosed amount. This acquisition serves to bolster the Apple intellectual property in the healthcare space as it continues to roll more health-oriented features in its hardware products. Tueo Health, a small Redwood City based start-up focused on monitoring asthma in sleeping pediatric patients. Major players in the respiratory monitoring devices market are Covidien, GE Healthcare, Philips Healthcare, ResMed, Siemens Healthcare, Merck & Co., Calando Pharmaceuticals, Quark Pharmaceuticals, Sirnaomics Inc., and Traversa Therapeutics. The regions covered in the respiratory monitoring devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the respiratory monitoring devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global respiratory monitoring devices market is segmented - 1) By Type: Capnographs, Gas Analyzers, Pulse Oximeters, Peak Flow Meters, Spirometers, Polysomnographs, Others 2) By End-User: Laboratories, Hospitals, Home Use 3) By Application: Chronic Obstructive Pulmonary Disease (COPD), Infectious Diseases, Asthma, Others

The market for N95 respirators and other surgical masks (face masks) consists of sales of N95 respirators and other surgical face masks used as personal protective equipment to protect the wearer from airborne particles and from liquid contaminating the face. The market consists of revenue generated by companies manufacturing the N95 respirators and surgical face masks by the sales of these products. The N95 respirators and other surgical masks (face masks) covered in this report is segmented by type into N95 respirator, common grade surgical mask, others (comfort masks/dust masks); by end-user into hospital and clinics, individual, industrial, others; by nature into reusable, disposable. The global masks (N95 respirators and other surgical masks) market is expected to decline from $8.16 billion in 2020 to $1.57 billion in 2021 at a compound annual growth rate (CAGR) of -80.8%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The N95 respirators and other surgical masks market is expected to reach $1.99 billion in 2025 at a CAGR of 6.1%. The masks market is experiencing an exponential growth due to the COVID-19 pandemic. This is because COVID-19 is a severe acute respiratory syndrome, which can be transmitted through airborne droplets, which masks can potentially block. Masks are therefore essential equipment for staff dealing with infectious patients. In addition, many other workers and individuals are using face masks as a precautionary measure. Rise in outbreak of airborne diseases contributed to the growth of the masks market. Airborne transmission of infectious agents refers to the transmission of disease caused by dissemination of droplet nuclei that remain infectious when suspended in air over long distance and time. Precautions that create a barrier and procedures that decrease or eliminate the microbe in the environment or on personal belongings, form the basis of interrupting transmission of direct contact diseases. The spread of airborne diseases like seasonal influenza kills 200–500 thousand people annually, influenza A (H1N1) caused 1,076 deaths in 2019, many among whom were healthy adults. These recent outbreaks remind us of the potential for a pandemic such as the Spanish flu of 1918–1920 which killed 50–100 million people and now it is the recent outbreak of COVID-19. This is expected to drive the growth of the masks market by several folds in the short term. Concerns regarding the disposal of non-woven disposables have always been a major challenge. Non-woven disposable surgical masks are made up of poly propylene which is a non-biodegradable material which cannot be decomposed by natural means. According to the World Bank research, nearly 1.3 billion tons of municipal solid waste are produced worldwide each year. It is estimated that about 19 billion tons of solid waste will be produced annually by 2025 worldwide. These factors are expected to have a negative impact on the disposable surgical mask market as regulatory agencies will take stringent actions regarding disposal of these non-biodegradable masks. This may have a negative impact on the market. The shift towards disposable devices in developed countries is one of the major trends in the market. Disposable masks eliminate the need for product sterilization and reduce cross-contamination with other reusable products. They are also cost-effective, and prevent contamination and reduce hospital stay, whereas reusable non-woven, masks need to be decontaminated, washed, sterilized for every reuse. Although, reusable surgical face masks can be sterilized and laundered for reuse but are less protective and more time-consuming for production as well as washing and sterilization for reuse. According to the FDA, surgical masks are not intended to be used more than once. This can rise the adoption of disposable respiratory masks. Disposable surgical face masks are often perceived to have protective advantages over reusable surgical face masks as they must be immediately discarded as bio-hazardous materials. Major players in the N95 respirators and other surgical masks market are 3M Company, Smith and Nephew, Molnlycke Healthcare, Medline Industries, Johnson and Johnson, DUKAL Corporation, Key Surgical, DYNAREX, CM, and ZHONGT. The regions covered in the N95 respirators and other surgical masks market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the N95 respirators and other surgical masks market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global masks (N95 respirators and other surgical masks) market is segmented - 1) By Type: N95 Respirator, Common Grade Surgical Mask, Others (Comfort Masks/Dust Masks) 2) By End-User: Hospital and Clinics, Individual, Industrial, Others 3) By Nature: Reusable, Disposable

Anesthesia And Respiratory Devices Market Definition

The anesthesia and respiratory devices market consists of sales of anesthesia and respiratory devices and related services by entities that manufacture such devices used in the diagnosis and treatment of respiratory diseases such as asthma, cystic fibrosis, and acute respiratory distress syndrome. Anesthesia devices are medical devices used to support the administration of anesthetics and medical gases such as nitrous oxide for the temporary induced loss of sensation or awareness. Anesthetics may include analgesia (used for relief from or prevention of pain) and temporary paralysis (used for muscle relaxation). Respiratory devices are used to provide medication or assist a patient who is having difficulty in breathing and cannot achieve adequate oxygen levels to maintain life.

The respiratory devices and equipment (therapeutic and diagnostic) market consists of sales of respiratory devices and equipment (therapeutic and diagnostic) and related services. Respiratory devices and equipment are used to provide medication or assist a patient who is having difficulty in breathing and cannot achieve adequate oxygen levels to maintain life. Patients with respiratory disorders such as asthma, cystic fibrosis, chronic obstructive pulmonary disease, and acute respiratory distress syndrome require respiratory devices and equipment. The global respiratory devices and equipment (therapeutic and diagnostic) market is expected to grow from $22.4 billion in 2020 to $24.22 billion in 2021 at a compound annual growth rate (CAGR) of 8.1%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $33.13 billion in 2025 at a CAGR of 8.1%. Global therapeutic respiratory devices and equipment market will be driven by the increase in diseases such as Chronic Obstructive Pulmonary Disease (COPD), asthma, and lung cancer. Growth in geriatric population, tobacco consumption, allergens and air pollutants increase the prevalence of respiratory diseases, in turn driving the global therapeutic respiratory devices market. According to World Health Organisation,4.9 million people die due to tobacco consumption, and smoking causes chronic obstructive pulmonary diseases (1 million deaths annually), cardiovascular and respiratory diseases (1.7 million deaths annually) and lung cancer (0.85 million deaths annually). According to an Italian journal, COPD in U.S. is estimated to be 10% in the population aged 75 years or over. According to Asthma UK, 5.4 million people in the UK are currently receiving treatment for asthma out of these 1.1 million are children and 4.3 million are adults. Longer duration of time taken in the approval process of the respiratory devices is restricting the respiratory devices and equipment market growth. Before a new respiratory device is introduced to the market, it takes 7.2 months for the FDA approval process, which adds to development costs to be borne by device manufacturers, thus acting as a restraint hindering the market growth. For instance, FDA reviews about 4,000 submissions every year and takes about 3 to 6 months in clearing most of them. In addition to this, to reduce incidences associated with the respiratory devices and ensure that the devices are safe and have least adverse reactions, Medicines and Healthcare products Regulatory Agency (MRHA), UK regulates and monitors the devices by restricting devices for use and sending field safety notice to correct the devices. These stringent approval processes and regulatory policies may impact the respiratory devices and equipment market. Companies in the respiratory devices and equipment market are increasingly investing in enhanced mechanical ventilators for efficient patient management. These mechanical ventilators use artificial intelligence to improve the patient management by examining, analyzing, integrating and incorporating data from extensive sources. These AI-enabled devices ensure consistency even in the absence of expert personnel, improve patients' treatment, limit clinical mistakes and predict prolonged mechanical ventilation by using artificial intelligence techniques. Some of the major companies offering intelligent mechanical ventilators such as Hamilton medical AG, Koninklijke Philips N.V. and others. In March 2019, Medicines and Healthcare products Regulatory Agency (MRHA), a regulatory body for respiratory devices of the UK, sent a medical device alert to Draeger, a medical device manufacturer, on its breathing circuits VentStar Helix and Set2go products, as the breathing circuits used in conjunction with devices are not compatible. These devices impacted patients health as cracks have formed in the breathing hose during ventilation. MRHA sent a field safety notice to correct the device to reduce incidences associated with these devices and promote the use of hose solely with devices which are declared as compatible in the instructions for use. Similarly, in March 2019, O-Two Medical Technologies, a Canada-based medical technology manufacturer, was sent an urgent field safety notice to stop use and return for inspection of O-Two eSeries Ventilators e700,e600 and e500 in order to inspect device functions, reset and analyze the data. Major players in the market are Smiths Medical, Philips Healthcare, GE Healthcare, Chart Industries and Invacare Corporation. The countries covered in the global respiratory devices and equipment (therapeutic and diagnostic) market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global respiratory devices and equipment (therapeutic and diagnostic) market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global respiratory devices and equipment (therapeutic and diagnostic) market is segmented - 1) By Type: Diagnostic devices, Therapeutic devices, Monitoring devices 2)By End User: Hospitals, Clinics, Homecare settings, Ambulatory service centers, 3) By Therapeutic Devices: Humidifiers, Nebulizers, Oxygen concentrators, Positive Airway Pressure (PAP) Devices, Ventilators, Others 4) By Diagnostic Devices: Spirometer, Polysomnographs, Peak Flow Meters 5) By Monitoring Devices: Pulse oximeters, Capnographs, Gas analyzers 6) By Application: Chronic Obstructive Pulmonary Disease (COPD), Asthma, Obstructive Sleep Apnea (OSA), Respiratory Distress Syndrome (RDS), Cystic Fibrosis, Pneumonia

The respiratory disposables market consists of sales of respiratory disposables and related services. Respiratory disposables include disposable resuscitators, disposable masks, disposable tubes, and other consumables and accessories. The global respiratory disposables market is expected to decline from $4.52 billion in 2020 to $3.74 billion in 2021 at a compound annual growth rate (CAGR) of -17.3%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $5.17 billion in 2025 at a CAGR of 8.4%. The high prevalence rate of respiratory diseases globally is driving the respiratory disposables market. Excessive smoking, exposure to toxic materials, adverse climate conditions, and air pollution are some of the main causes which are leading to a rise in respiratory diseases such as asthma, lung cancer, Chronic Obstructive Pulmonary Disease (COPD), and obstructive sleep apnea (OSA). According to a study, around 65 million people suffer from the chronic obstructive pulmonary disease (COPD) and around 3 million people die every year because of this disease. It was also reported that around 334 million people suffer from asthma diseases caused by air pollution as well as tobacco smoke, toxic disposable devices. These factors are increasing the demand for the treatment of respiratory ailments, thus driving the respiratory diseases market. The respiratory disposables market is being restrained due to stringent regulatory policies. Regulatory agencies and governments across various countries are imposing stringent restrictions on product approval and launch, this is limiting the market growth. For instance, FDA banned Amphastar Pharmaceutical’s Primatene product, an albuterol CFC inhaler for asthma because ozone-depleting chlorofluorocarbon (CFC) propellants have depleted the ozone layer. The FDA rejected Amphastar’s first attempt to bring a reformulated version of Primatene mist to market. The FDA rejected another application for Primatene Mist. which resulted in a rise in development costs and potential sales loss due to delays in product launch, thus restraining the Respiratory disposables market. Rapid advances in technology are driving innovation in respiratory disposable manufacturing. Areas of particular development are likely to be AIR gel technology, wearable technologies, and 3D printing technology. These technologies are being used in the manufacturing of respiratory disposables, resulting in higher productivity, lower costs, and higher margins. Companies in this market are increasingly focusing on AIR gel technology, in which gel is incorporated into the bag on the edges of the mask which helps to the protection of the skin and creates a bridge to minimize the irritation of the skin and for effective sealing. For example, Vyair medical prepared Veraseal 2 disposable mask, used for acute care with AIR gel technology and advantage of vented and non-vented versions. Similarly, Sleepnet prepared Mojo ventilation masks with Airgel technology. In the USA, occupational safety and health administration (OSHA) regulates all respiratory medical equipment, guidelines for which are specified in 29 CFR 1910. 134. Under OSHA, the national institute for occupational safety and health/national personal protective technology laboratory (NIOSH/ NPPTL) provides a market approval certificate and FDA approves the product for marketing. Before market approval, all the medical devices should be analyzed appropriately by performing a compatibility test within a hospital environment. They are tested on an Electrical bench and Non-clinical performance testing is also required. Moreover, proper software verification, validation, and hazard analysis must be performed. Labels on the devices are required to include the purpose of the device. In April 2018, Vyaire Medical acquired Acutronic Medical for an undisclosed amount. The acquisition is expected to enhance Vyaire’s product portfolio, technological capabilities, and expand their intellectual capital. Acutronic Medical develops and sells ventilation solutions for NICU's/PICU's, ICU's, and Intensive Care Transportation. The company was founded in 1981 and is headquartered in Switzerland. Major players in the market are Fisher & Paykel, Becton Dickinson Company, Ambu A/S, Smiths Medical, Armstrong Medical. The countries covered in the global respiratory disposables market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global respiratory disposables market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global respiratory disposables market is segmented - 1) By Type: Masks, Tubes, Inhalers, Others 2) By End User: Hospitals, Clinics, Ambulatory Care Centers, Others 3) By Disease Indications: Asthma, Chronic Obstructive Pulmonary Disorder, Tuberculosis, Lung Cancer, Other Chronic Respiratory Diseases 4) By Application: Adult, Pediatric & Neonatal

The respiratory devices and equipment (diagnostic) market consist of sales of diagnostic respiratory devices and equipment and related services by entities (organizations, sole traders, and partnerships) that manufacture respiratory devices and equipment. Respiratory devices and equipment are used in the diagnosis of respiratory disorders such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease. Only goods and services traded between entities or sold to end consumers are included. The global respiratory devices and equipment (diagnostic) market is expected to grow from $5.804 billion in 2020 to $6.233 billion in 2021 at a compound annual growth rate (CAGR) of 7.4%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $8.583 billion in 2025 at a CAGR of 8%. The increasing prevalence of various respiratory diseases contributed to the global respiratory devices and equipment market’s growth by increasing the use of diagnostic devices and equipment for diagnosis and treatment. Diseases such as chronic obstructive pulmonary disease (COPD) are more prevalent in the geriatric population. COPD is a type of obstructive lung disease that results in long-term breathing problems. According to the United Nations (UN), the global geriatric population was 962 million in 2017. Also, the Global Burden of Disease Study reported a prevalence of 251 million cases of COPD globally in 2016. In Canada, 3.8 million people over the age of one are living with asthma and 2.0 million are living with chronic obstructive pulmonary disease (COPD) in 2018, both of which can impact a person's ability to breathe. Thus, the increased number of such cases has surged the demand for diagnostic devices and equipment, therefore driving the market’s growth. Stringent regulatory practices are expected to negatively impact the growth of diagnostic respiratory devices in the forecast period. In the USA, respiratory devices undergo a strict approval process as they come under Class III devices (that pose a significant risk to patients) as per the Food and Drug Administration (FDA) classification of medical devices. These devices require clinical evidence that supports their intended use unlike, Class I and II devices, to receive marketing approval. In countries such as China, the approval process for medical devices, especially for devices used for support or sustenance, is strict and time-consuming. Such a process has slowed the entry of medical devices into the market, thus restraining the growth. Companies in the market are increasingly investing in portable and wireless diagnostic respiratory devices. The trend is being driven by the ease of handling, cost-effectiveness, advanced features of these devices, and their suitability for use at home care organizations. Innovative technology-enabled portable respiratory devices are being launched into the market, which unlike traditional devices, can be used for immediate diagnosis of vital signs, for example, the patients’ respiratory rate and the pulse rate. For instance, in 2019, the US Food and Drug Administration approved MediPines Corporation's non-invasive portable medical device, which provides clinicians with real-time pulmonary parameters and insights to support rapid triage and treatment decisions for respiratory conditions. In June 2020, AireHealth acquired BreathResearch for an undisclosed amount. The deal comprises the acquisition of IP, research, and patents, which include work on machine learning analytics for respiratory condition tracking. BreathResearch is a US-based company engaged in converting the airwaves of breathing into sound waves producing new respiratory analytics which improves health, fitness, and performance. The major players covered in the global respiratory devices and equipment (diagnostic) market are ResMed. Inc., Medtronic PLC, Massimo Corporation, Fisher & Paykel Healthcare Limited, Koninklijke Philips N.V., Smiths Medical, GE Healthcare, Chart Industries, Philips Healthcare, Becton Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific Inc., Alere Inc., Teleflex Incorporated, General Electric Healthcare Limited, Invacare Corporation, Vyaire Medical Inc, Dragerwerk AG & Co. KGaA, Getinge AB, Drager Medical GmbH, Maquet Corp., Invacare Corp., Biomérieux, Bio-Rad Laboratories Inc, Cosmed, Seegene Inc, Sdi Diagnostics. The countries covered in the global respiratory devices and equipment (diagnostic) market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global respiratory devices and equipment (diagnostic) market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global respiratory devices and equipment (diagnostic) market is segmented - 1) By Product: Instruments And Devices, Assays And Reagents, 2) By Test Type: Traditional Diagnostic Tests, Mechanical Tests, Imaging Tests, Molecular Diagnostic Tests, 3) By Disease Type: Chronic Obstructive Pulmonary Disease, Lung Cancer, Asthma, Tuberculosis, Other Diseases, 4) By End User: Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories, Other End Users

The respiratory diseases drugs market consists of sales of respiratory diseases drugs and related services by entities (organizations, sole traders and partnerships) that produce drugs to treat respiratory diseases such as asthma, acute bronchitis, emphysema, cystic fibrosis and other diseases. This industry includes establishments that produce anti-asthmatics and COPD drugs to prevent acute attacks caused by respiratory diseases and cough and cold preparations to treat cough and cold. Some of the major drugs in the market include antimuscarinics, corticosteroids, Codral®, Coldrex® and Lemsip®. The respiratory diseases drugs market is segmented into anti-asthmatics and copd drugs; and cough and cold preparations. The global respiratory diseases drugs market is expected to decline from $90.32 billion in 2020 to $79.82 billion in 2021 at a compound annual growth rate (CAGR) of -11.6%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $98.81 billion in 2025 at a CAGR of 5%. North America was the largest region in the global respiratory diseases drugs market, accounting for 48% of the market in 2020. Western Europe was the second largest region, accounting for 19% of the global respiratory diseases drugs market. Africa was the smallest region in the global respiratory diseases drugs market. During the historic period, the growth of the respiratory diseases drugs market was restrained by patent expiration of branded respiratory diseases drugs. In general, pharmaceutical companies invest a large sum of money in the drug development process and patents. During the patency period, the company holding the patent holds exclusivity for the manufacturing and distribution of drugs. Post expiration of patency, generic versions of the drugs are manufactured by other companies with prices much lower than the original branded drugs. Overall, this negatively impacts the growth of the market in terms of value. Companies in the respiratory drugs market are offering drugs for customized individual treatment for better treatment against respiratory diseases. Personalized medicine, also referred to as precision medicine, aims to provide medical care according to the patient’s individual characteristics and genetic makeup. Precision therapies are increasingly being adopted in the respiratory drugs market as firms increasingly let go of the one-size-fits-all model for common respiratory conditions. Companies such as GSK, Teva Pharmaceuticals and AstraZeneca have already invested in personalized medicine for respiratory issues such as asthma. For example, PTC Therapeutics, is developing a drug, which aims to cater to a respiratory mutation which affects about 10% of the population. Companies manufacturing respiratory drugs are increasingly using biomarkers in the drug development process to reduce the time taken to bring the product into the market. Biomarkers are biological indicators which are objectively measured and evaluated for biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention. It can also help predict the drug efficacy faster than conventional clinical endpoints, the point at which an undesired or abnormal effect of the drug is observed indicating withdrawal from therapy. Companies in this market are investing in the development of biomarkers for use in various activities such as tracking drug activity, the pharmacodynamics (relationship between the drug concentration at the site of action and the biochemical and physiological effect) of drugs and to study diseases and treatment pathways. Companies such as Genentech and Janssen are increasingly investing in the use of biomarkers for understanding the efficacy of a potential respiratory drug. For example, Janssen has partnership with U-BIOPRED (unbiased biomarkers in prediction of respiratory disease outcomes), a group in Europe that aims to understand more about severe asthma. The major players covered in the global respiratory diseases drugs market are GlaxosmithKline Plc, AstraZeneca Plc, Merck & Co, Novartis AG, Johnson & Johnson. The countries covered in the global respiratory diseases drugs market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam. The regions covered in the global respiratory diseases drugs market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global respiratory diseases drugs market is segmented - 1) By Type: Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route Of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs